Company intelligence / Profile preview
PharmNovo
Lund, Swedenpharmnovo.com ↗
- Ownership
- Private
- Employees
- ~9
- Development stage
- Other
01
Overview
PharmNovo’s lead candidate, PN6047, is a first-in-class selective delta opioid receptor agonist designed to treat neuropathic pain without the side effects or addiction potential of traditional opioids. PN6047 has completed Phase I trials with a proven safety profile and is preparing to enter Phase II proof-of-concept studies. Preclinical and early clinical data indicate potent efficacy in neuropathic pain with minimal side effects.
- Therapeutic areas
- PulmonologyPsychiatryNeurology
- Modalities
- Small moleculeDelta opioid receptor agonist (DORA)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on PharmNovo.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PharmNovo.